Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:755-759

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mayet, J.
Right arrow Articles by Thom, S. A. McG.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mayet, J.
Right arrow Articles by Thom, S. A. McG.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*BENDROFLUMETHIAZIDE
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Hypertrophy
Right arrow Echocardiography

(Hypertension. 2000;36:755.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Improvement in Midwall Myocardial Shortening With Regression of Left Ventricular Hypertrophy

Jamil Mayet; Ben Ariff; Balvinder Wasan; Neil Chapman; Manjit Shahi; Neil R. Poulter; Peter S. Sever; Rodney A. Foale; Simon A. McG. Thom

Correspondence to Dr J. Mayet, Department of Cardiology, St Mary’s Hospital, Praed Street, Paddington, London W2 1NY, UK. E-mail j.mayet{at}ic.ac.uk

Abstract—Despite normal indices of left ventricular (LV) chamber function, patients with LV hypertrophy (LVH) due to hypertension are thought to have depressed midwall systolic shortening compared with normotensives. The aims of the present study were (1) to confirm this observation and (2) to assess the effects of antihypertensive therapy that cause regression of LVH on LV systolic function assessed at both the midwall and endocardium. Thirty-eight previously untreated hypertensive subjects with LVH underwent echocardiography and were compared with 38 normotensive control subjects. Comparisons between the group with LVH and the control group revealed no significant differences in cardiac output (4.32±0.23 versus 4.55±0.21 L/min), ejection fraction (62.5±2% versus 66.4±1.07%), or endocardial fractional shortening (34.5±1.45% versus 37.0±0.82%), but shortening assessed at the midwall was significantly less in the group with LVH (17.9±1.11% versus 21.6±0.63%, P<0.01). Subsequently, 32 patients with uncontrolled hypertension (24 previously untreated and 8 on existing antihypertensive therapy) underwent treatment with ramipril, with the addition of felodipine and bendrofluazide if required, to reduce blood pressure to <140/90 mm Hg. These 32 patients underwent echocardiography at baseline, after blood pressure control, and after an additional 6 months of tight blood pressure control. Good blood pressure control was achieved after 6 months compared with baseline (143/86±2.8/1.4 versus 174/103±4.1/1.9 mm Hg; P<0.01) with significant regression of LV mass index (124±3.4 versus 145±3.8 g/m2, P<0.01). LV fractional shortening assessed at the midwall improved with regression of LVH (21.9±0.84 and 18.7±1.19%, P<0.05), with posttreatment midwall shortening being similar to that of the normal control subjects evaluated in the first study. Hypertensive patients with LVH have depressed midwall systolic shortening despite normal indices of LV chamber function. Regression of LVH after good blood pressure control improved midwall shortening to normal levels.


Key Words: hypertension, detection and control • ventricular function • hypertrophy • blood pressure • systole • echocardiography




This article has been cited by other articles:


Home page
HypertensionHome page
A. Y-M. Wang, M. Wang, C. W-K. Lam, I. H-S. Chan, Y. Zhang, and J. E. Sanderson
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease
Hypertension, July 1, 2008; 52(1): 107 - 114.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
L. H Naylor, L. F Arnolda, J. A Deague, D. Playford, A. Maurogiovanni, G. O'Driscoll, and D. J Green
Reduced ventricular flow propagation velocity in elite athletes is augmented with the resumption of exercise training
J. Physiol., March 15, 2005; 563(3): 957 - 963.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J. Mayet and A. Hughes
Cardiac and vascular pathophysiology in hypertension
Heart, September 1, 2003; 89(9): 1104 - 1109.
[Full Text] [PDF]


Home page
CirculationHome page
K. Wachtell, V. Palmieri, M. H. Olsen, E. Gerdts, V. Papademetriou, M. S. Nieminen, G. Smith, B. Dahlof, G. P. Aurigemma, and R. B. Devereux
Change in Systolic Left Ventricular Performance After 3 Years of Antihypertensive Treatment: The Losartan Intervention for Endpoint (LIFE) Study
Circulation, July 9, 2002; 106(2): 227 - 232.
[Abstract] [Full Text] [PDF]